PT Inquest is an online journal club. Hosted by Jason Tuori, Megan Graham, and Chris Juneau, the show looks at an article every week and discusses how it applies to current physical therapy practice.
…
continue reading
İçerik ReachMD tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan ReachMD veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
Player FM - Podcast Uygulaması
Player FM uygulamasıyla çevrimdışı Player FM !
Player FM uygulamasıyla çevrimdışı Player FM !
Going Beyond Today’s Assessments to Confirm COPD, Are Biomarkers Key?
MP3•Bölüm sayfası
Manage episode 456217370 series 3128163
İçerik ReachMD tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan ReachMD veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
CME credits: 0.50
Valid until: 18-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/going-beyond-todays-assessments-to-confirm-copd-are-biomarkers-key/27035/
Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.
…
continue reading
Valid until: 18-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/going-beyond-todays-assessments-to-confirm-copd-are-biomarkers-key/27035/
Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.
458 bölüm
MP3•Bölüm sayfası
Manage episode 456217370 series 3128163
İçerik ReachMD tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan ReachMD veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
CME credits: 0.50
Valid until: 18-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/going-beyond-todays-assessments-to-confirm-copd-are-biomarkers-key/27035/
Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.
…
continue reading
Valid until: 18-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/going-beyond-todays-assessments-to-confirm-copd-are-biomarkers-key/27035/
Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.
458 bölüm
すべてのエピソード
×Player FM'e Hoş Geldiniz!
Player FM şu anda sizin için internetteki yüksek kalitedeki podcast'leri arıyor. En iyi podcast uygulaması ve Android, iPhone ve internet üzerinde çalışıyor. Aboneliklerinizi cihazlar arasında eş zamanlamak için üye olun.